Literature DB >> 29387198

Necrosis of osteosarcoma cells induces the production and release of high-mobility group box 1 protein.

Jiyu Yang1, Zhiqiang Ma1, Yanlong Wang1, Zengkun Wang1, Youwei Tian1, Yingchao Du1, Wei Bian1, Yongfu Duan1, Jianyu Liu1.   

Abstract

Osteosarcoma is among the commonly observed malignancies worldwide. High-mobility group box 1 protein (HMGB1) is a highly conserved protein and is involved in the progression of various types of human cancer. The aim of the present study was to explore whether the level of HMGB1 was involved in the necrosis of osteosarcoma cells. Doxorubicin (DXR), as an inducer of necrosis, was administered to human osteosarcoma cell lines (MG63, Saos-2 and U2OS), and the results indicated that 0.5 µg/ml DXR significantly induced the necrosis of MG63 cells (P<0.01), while 0.5 and 1.0 µg/ml DXR suppressed the viability of MG63 and U2OS cells (P<0.05), relative to untreated controls. Additionally, treatment with DXR was observed by western blot analysis to markedly increase the expression levels of HMGB1 in MG63 cells, and to significantly increase the levels of secreted HMGB1 in the supernatants of MG63 and U2OS cells (P<0.01). In conclusion, cell necrosis increased the level of HMGB1 in osteosarcoma cells, as well as the level of secreted HMGB1 in cell supernatants. Therefore, HMGB1 may be a potential target in molecular therapy for patients with osteosarcoma.

Entities:  

Keywords:  doxorubicin; high-mobility group box 1 protein; necrosis; osteosarcoma

Year:  2017        PMID: 29387198      PMCID: PMC5768087          DOI: 10.3892/etm.2017.5415

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  31 in total

Review 1.  Review of the molecular pathogenesis of osteosarcoma.

Authors:  Jin-Peng He; Yun Hao; Xiao-Lin Wang; Xiao-Jin Yang; Jing-Fan Shao; Feng-Jin Guo; Jie-Xiong Feng
Journal:  Asian Pac J Cancer Prev       Date:  2014

2.  miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy.

Authors:  Xuefeng Li; Sijia Wang; Yan Chen; Guifeng Liu; Xiaoyu Yang
Journal:  Tumour Biol       Date:  2014-03-09

3.  Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.

Authors:  Markus Uhl; Ulrich Saueressig; Miriam van Buiren; Udo Kontny; Charlotte Niemeyer; Gabriele Köhler; Kamil Ilyasov; Mathias Langer
Journal:  Invest Radiol       Date:  2006-08       Impact factor: 6.016

4.  The relation of tumour necrosis and survival in patients with osteosarcoma.

Authors:  Xin Li; Adedayo O Ashana; Vincent M Moretti; Richard D Lackman
Journal:  Int Orthop       Date:  2011-02-26       Impact factor: 3.075

5.  HMGB1 knockdown effectively inhibits the progression of rectal cancer by suppressing HMGB1 expression and promoting apoptosis of rectal cancer cells.

Authors:  Zhiwei Wang; Xiaoyan Wang; Jiantian Li; Cheng Yang; Zhiyuan Xing; Ruiyun Chen; Fei Xu
Journal:  Mol Med Rep       Date:  2016-05-24       Impact factor: 2.952

Review 6.  Spontaneous pneumothorax in children with osteosarcoma: report of three cases and review of the literature.

Authors:  M Fayda; R Kebudi; Y Dizdar; O Gorgun; F Gun; G Aksu; I Ayan
Journal:  Acta Chir Belg       Date:  2012 Sep-Oct       Impact factor: 1.090

7.  Assessing the percent of necrosis after neoadjuvant chemotherapy with 24hr infusional cisplatin/3 days Doxorubicin intermittent with Ifosfamide-Doxorubicin for osteosarcoma.

Authors:  Mozhgan Aalam Samimi; Nooshin Mirkheshti; Abdolreza Pazouki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014

8.  Association between an elevated level of HMGB1 and non-small-cell lung cancer: a meta-analysis and literature review.

Authors:  Quansong Xia; Juan Xu; Huoying Chen; Yanzhang Gao; Feili Gong; Liya Hu; Li Yang
Journal:  Onco Targets Ther       Date:  2016-06-29       Impact factor: 4.147

9.  HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma.

Authors:  Qingbing Meng; Jie Zhao; Hongbing Liu; Guoyou Zhou; Wensheng Zhang; Xingli Xu; Minqian Zheng
Journal:  Tumour Biol       Date:  2014-08-29

10.  Osteosarcoma in pediatric patients and young adults: a single institution retrospective review of presentation, therapy, and outcome.

Authors:  Candace L Haddox; Gang Han; Leon Anijar; Odion Binitie; G Douglas Letson; Marilyn M Bui; Damon R Reed
Journal:  Sarcoma       Date:  2014-04-30
View more
  4 in total

Review 1.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

2.  miR-877-3p inhibits tumor growth and angiogenesis of osteosarcoma through fibroblast growth factor 2 signaling.

Authors:  Mingji Chen; Zhi Li; Lei Cao; Chi Fang; Rufeng Gao; Chao Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  RNA 5-methylcytosine status is associated with DNMT2/TRDMT1 nuclear localization in osteosarcoma cell lines.

Authors:  Gabriela Betlej; Tomasz Ząbek; Anna Lewińska; Dominika Błoniarz; Iwona Rzeszutek; Maciej Wnuk
Journal:  J Bone Oncol       Date:  2022-07-30       Impact factor: 4.491

4.  Data-Driven Mathematical Model of Osteosarcoma.

Authors:  Trang Le; Sumeyye Su; Arkadz Kirshtein; Leili Shahriyari
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.